Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was incorporated in 1998 and is based in Austin, Texas.
Frequently asked questions
What sector does Cassava Sciences Inc (PX91) operate in?
Cassava Sciences Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Cassava Sciences Inc (PX91) current stock price?
As of the latest data, Cassava Sciences Inc stock price is €0.54, with a previous close of €0.56. Cassava Sciences Inc lost -€0.02 in the last trading session, representing a -3.6% loss.
What is Cassava Sciences Inc (PX91) current market capitalization?
Cassava Sciences Inc market cap is approximately 25.89 million.
What is Cassava Sciences Inc (PX91) Earnings Per Share (EPS)?
The trailing EPS is -€0.75.
What is Cassava Sciences Inc (PX91) EBITDA?
Cassava Sciences Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -8.01 million.
Does Cassava Sciences Inc (PX91) pay dividends?
No. Cassava Sciences Inc does not pay a dividend.
When is Cassava Sciences Inc (PX91) next earnings report?
Cassava Sciences Inc is expected to release its next earnings report on September 30, 2026.
What is Cassava Sciences Inc (PX91) beta (volatility) score?
Cassava Sciences Inc has a beta of -0.660, indicating lower volatility than the overall market.
